Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
finance.yahoo.com/news/uniqure-announ... uniQure Announces Will Lewis as New Board Member GlobeNewswire uniQure June 12, 2014 6:15 AM AMSTERDAM, Netherlands, June 12, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, today announced that Will Lewis has joined uniQure's Supervisory Board as of June 11th, 2014. Mr. Lewis has been serving as President and Chief Executive Officer and as a member of the Board of Directors of Insmed, a biopharmaceutical company specialized in inhalation therapies for orphan lung diseases, since 2012. "Will has a tremendous track record in achieving success for companies much like ours," said Jorn Aldag, CEO of uniQure. "His exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company." "uniQure is at the forefront of gene therapy, not only aiming at curative treatments for orphan diseases but seeking to have a broader impact on human health by developing therapies to treat diseases such as Parkinson's," commented Will Lewis, MBA/JD. "Having been involved in both the scientific and financial aspects of management in the past, I am committed to bring my expertise in both areas to uniQure." Mr. Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. During his tenure at Aegerion, Mr. Lewis played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications. Prior to Aegerion, Mr. Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raises and advisory work valued at more than $20 billion. Mr. Lewis also serves as a member of the Board of Directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Mr. Lewis holds a Bachelor of Arts degree cum laude from Oberlin College and a Master of Business Administration/Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government. About uniQure uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of Glybera, and the risk that our collaborations with Chiesi or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. uniQure: Aicha Diba Investor Relations Direct : +31 20 240 6100 Main: +31 20 566 7394 IR@uniQure.com Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +1 781 235 3060gschweitzer@macbiocom.com HUG#1792441
helaas typefoutje (heb mijn school wel afgemaakt, maar geen typediploma... ;-)) Misschien dat een moderator relaeses in releases kan omzetten...mij lukt het niet meer, want kan alleen de posting wijzigen en niet de titel.
finance.yahoo.com/news/uniqure-secure... uniQure Secures Additional $10M Venture Loan from Hercules Capital Restructured Venture Debt Financing for Expansion and Advancement of Gene Therapy Pipeline GlobeNewswire uniQure 15 minutes ago AMSTERDAM, the Netherlands, July 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, today announced the closing of an additional $10 million venture debt loan with Hercules Technology Growth Capital, Inc. (HTGC), increasing the total loan amount to $20 million including the initial $10 million that uniQure announced in July 2013. "The expansion of our original agreement with Hercules and its restructuring to incorporate further beneficial terms for uniQure provide us with greater balance sheet strength and flexibility. We will devote our additional capital both to rapidly advancing our pipeline and to accessing early-stage opportunities that will leverage our gene therapy platform and manufacturing expertise," commented Jorn Aldag, uniQure Chief Executive Officer. "Accessing the best third party programs in early development enables us to further expand our high quality pipeline, sustaining the Company's leadership position in gene therapy." The initial agreement with HTGC earmarked a portion of the venture debt financing to support the build-out of a state-of-the-art AAV-based gene therapy manufacturing facility in Lexington, MA. uniQure anticipates the facility to be fully operational in 2015. About uniQure uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com About Hercules Technology Growth Capital Hercules Technology Growth Capital, Inc. (HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy and renewables technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.2 billion to over 270 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. More information on the company can be found at www.htgc.com. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of Glybera, and the risk that our collaborations with Chiesi or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. uniQure: Aicha Diba Investor Relations Direct: +31 20 240 6100 Main: +31 20 566 7394 IR@uniQure.com Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +1 781 235 3060gschweitzer@macbiocom.com
Chiesi and uniQure Provide Update on Glybera(r) Launch Read more: www.nasdaq.com/press-release/chiesi-a...
Chiesi and uniQure Provide Update on Glybera(r) Launch GlobeNewswire uniQure 5 hours ago AMSTERDAM, the Netherlands, and PARMA, Italy, Aug. 4, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading international pharmaceutical company, today provided an update on preparations relating to the launch of Glybera(R) (alipogen tiparvovec), the first gene therapy product approved in the European Union, for the treatment of the orphan disease lipoprotein lipase deficiency (LPLD). Chiesi has exclusive rights to commercialize Glybera in the EU and selected additional territories. Expanding on the original launch strategy, Chiesi and uniQure decided to include in the pricing and reimbursement applications for launch, the six-year follow-up pancreatitis data from the study AMT 011-05, announced June 3, 2014. As a consequence, Chiesi now expects to launch Glybera in the fourth quarter of 2014/first quarter of 2015. "We are fully supportive of Chiesi's approach to include additional data demonstrating multiyear benefit for a one time treatment in our pricing and reimbursement documentation. Adding long-term data will significantly strengthen the quality of the application," said Jorn Aldag, CEO of uniQure. Chiesi CEO Ugo Di Francesco added: "Whilst pricing and reimbursement discussions are on-going, Chiesi has commenced the setup of a number of expert treatment centres which will be able to offer Glybera for the appropriate patients and manage them post treatment." Developed by uniQure, Glybera was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with LPLD, a potentially life-threatening, orphan metabolic disease. Glybera currently is not approved for use outside of the European Union. Glybera is indicated for the treatment of adult patients diagnosed with familial LPLD confirmed by genetic testing and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. LPLD results in hyper-chylomicronemia, or dramatic and potentially life-threatening increases in the level of large fat-carrying particles, called chylomicrons, in the blood after eating. In many cases, LPLD and the associated elevated levels of chylomicrons can cause acute and potentially life-threatening inflammation of the pancreas, known as pancreatitis, thus leading to frequent hospitalizations. Recurrent pancreatitis can lead to chronic abdominal pain, pancreatic insufficiency - which is an inability to properly digest food due to a lack of digestive enzymes made by the pancreas -, and diabetes. There is no other approved treatment for LPLD.
De koers reageert slecht op bovenstaand nieuws, het valt blijkbaar weer tegen.
eigenlijk is het een hele goede reactie...op dagen zonder nieuws ging het soms veel harder onderuit. Het wordt voor kennisgeving aangenomen en de lage omzet vandaag is nietszeggend. ander algemeen vraagje: is bij iemand de conversie van certificaten naar aandelen al gewoon afgerond? Bij mij (ALEX)namelijk nog niet en dat zou wellicht het ontbreken van de enorme verkoopdruk kunnen verklaren als dat voor iedere certificaathouder geldt... ;-)
invoorentegenspoed schreef op 4 augustus 2014 23:38 :
eigenlijk is het een hele goede reactie...op dagen zonder nieuws ging het soms veel harder onderuit.
Het wordt voor kennisgeving aangenomen en de lage omzet vandaag is nietszeggend.
ander algemeen vraagje: is bij iemand de conversie van certificaten naar aandelen al gewoon afgerond?
Bij mij (ALEX)namelijk nog niet en dat zou wellicht het ontbreken van de enorme verkoopdruk kunnen verklaren als dat voor iedere certificaathouder geldt... ;-)
Dat laatste was tevens mijn gedachte, denk niet dat er al veel geconverteerd is. Bij mij iig ook nog niet (DeGiro). We zullen zien of de omzetten vandaag een stap gaan maken.
Bij Binck ook nog niets geconverteerd.
streber schreef op 5 augustus 2014 12:35 :
Bij Binck ook nog niets geconverteerd.
Ik denk dat de grote aandeelhouders sneller kunnen omwisselen en dus eerder kunnen verkopen, bovendien kunnen zij ook aandelen lenen en alvast verkopen.
Stukken zijn inmiddels verhandelbaar (DeGiro).
Rien.Nevaplus schreef op 5 augustus 2014 16:32 :
Stukken zijn inmiddels verhandelbaar (DeGiro).
Wat een feest...!! En nu nog proberen te verkopen....
DeZwarteRidder schreef op 5 augustus 2014 16:39 :
[...]
Wat een feest...!!
En nu nog proberen te verkopen....
Hahaha, lolbroek. Dat was een mededeling voor aandeelhouders, waar jij blijkbaar niet onder valt. Waarom investeer jij zoveel tijd in dit forum als je geen belang hebt? Ofwel je bent een slechte verliezer (die flink het schip in is gegaan met AMT oid) ofwel je hebt geen andere hobbies.
Bij Binck zijn ze nog niet geconverteerd en dus ook nog niet te verhandelen. Het probleem is bekend en men is er mee bezig, misschien wel een tip wanneer je ook Binck rekeninghouder bent om je te melden bij Binck en je rekeningnummer door te geven. Wellicht dat het probleem dan opgeschaald wordt wanneer meerdere certificaathouders zich melden en ze eerder geconverteerd worden. Ik heb om een verwachting gevraagd wanneer dit opgelost zou zijn, hier kon men nog geen uitspraak over doen. Er is een ander team die dit behandeld, maar ik word als het goed is teruugebeld.
Rien.Nevaplus schreef op 5 augustus 2014 18:03 :
[...]
Hahaha, lolbroek. Dat was een mededeling voor aandeelhouders, waar jij blijkbaar niet onder valt. Waarom investeer jij zoveel tijd in dit forum als je geen belang hebt? Ofwel je bent een slechte verliezer (die flink het schip in is gegaan met AMT oid) ofwel je hebt geen andere hobbies.
De spijker op zijn kop: eenzame oude mannen die als hobby hebben om te zieken op forums.
Tot op heden nog niets vernomen en nog geen verandering van certificaten naar aandelen waar te nemen in mijn portefeuille bij Binck.
Ik had mijn certificaten nog op mijn npex rekening laten staan. Ik zie zojuist dat deze zijn omgezet naar gewone QURE aandelen. Nu even kijken per wanneer ik ze laat overzetten naar de ING Bank. Volgens de berichtgeving van zowel npex als de ING moet het binnenkort mogelijk zijn om via de ING in aandelen QURE te handelen. Dit is op het moment nog niet het geval. Als er iemand meer info heeft, bv. een datum, dan verneem ik het graag.
Ik heb net met Binck gebeld en om een update gevraagd, naar het blijkt moet de uitleverende instantie de stukken/aandelen nog leveren. Dit had officieel gisteren moeten gebeuren, maar bij buitenlandse instellingen duurt het soms nog wel een dag later. Of we ze vandaag bij Binck nog ontvangen is moeilik te zegge, ik begreep van de medewerkers dat men er wel bovenop zit.
Hartelijk dank voor uw e-mail. U heeft een vraag over de omzetting van uw aandelen Uniqure. Op dit moment is de omzetting van uw aandelen Uniqure ingang. Wij wachten echter nog op de aandelen. Zodra wij de aandelen hebben ontvangen worden deze in uw portefeuille gedeponeerd. Ik vertrouw erop u met deze informatie van dienst te zijn. Vragen? Als u nog vragen of opmerkingen heeft, zijn wij u uiteraard graag van dienst. De medewerkers van de Servicedesk zijn bereikbaar op werkdagen van 8:00 uur tot 22:00 uur en op zaterdag van 10:00 uur tot 17:00 uur op telefoonnummer 020 - 521 81 80 of per e-mail op info@alex.nl .
Nog even afwachten dus, in ieder geval een prettige bijkomstigheid dat dat Uniqure vandaag weer eens in de plus staat. Koers is afgelopen weken weer aardig teruggevallen en leek zich net mooi te gaan herstellen. Ik ben benieuwd wat de meeste certificaathouders die aandelen krijgen er tegen deze koers mee gaan doen. Ik ben wel voornemens om ze even vast te houden de komende tijd en wil ze nog niet kwijt voor deze koers. Er moet nog meer in het vat zitten...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
865,35
0,00%
EUR/USD
1,0677
+0,06%
FTSE 100
7.847,99
+0,35%
Germany40^
17.771,70
+0,01%
Gold spot
2.374,77
+0,58%
NY-Nasdaq Composite
15.683,37
-1,15%
Stijgers
Dalers